Get the latest updates from Collaborations Pharmaceuticals, Inc by checking out The Catalyst Newsletter for 2024!

NIEHS has awarded a $2,044,647 SBIR grant to Collaborations Pharmaceuticals, Inc. to develop new acetycholinesterase reactivators with Battelle

Collaborations Pharmaceuticals, Inc., are pleased to announce their invitation from Reckitt to participate in The Science Inside Symposium 2024

Collaborations Pharmaceuticals, Inc., announce the opening of a new office in Raleigh, NC, to house their software development, business and operations teams.

Collaborations Pharmaceuticals, Inc. has developed a registry for Batten Disease CLN1 In order to find patients with this rare disease and gather information.

Collaborations Pharmaceuticals and Battelle published a new paper which demonstrated that an FDA approved drug may help in VX poisoning.

The National Institute of Neurological Disorders and Stroke has awarded a $3,953,139 SBIR grant to Collaborations Pharmaceuticals, Inc. for a Rare Disease

Can-Fite signed an agreement with Collaborations Pharmaceuticals, a leading expert in Artificial Intelligence and Machine Learning

RALEIGH, NORTH CAROLINA, USA, September 20, 2023/EINPresswire.com/ -- Collaborations Pharmaceuticals, Inc. (CPI) and the Texas Medical Branch (UTMB) are pleased to announce that they were awarded a $295,000 Phase I Small Business Innovation Research (SBIR) grant

PsychoGenics Inc. (PsychoGenics) and Collaborations Pharmaceuticals, Inc. (CPI) are pleased to announce that they were awarded a $1million Phase I Small Business Innovation Research (SBIR) grant, to use their combined AI tools to design new drugs for mental health disorders.

A new paper published in Antiviral Research describes a new inhibitor of Enterovirus-D68 and Coxsackie B5.

Raleigh –Collaborations Pharmaceuticals, Inc. announces the publication of a paper detailing their generative molecule design software, MegaSyn.

Raleigh – Collaborations Pharmaceuticals, Inc. and international collaborators publish paper on pyronaridine and its protection against infection with SARS-CoV-2.

Collaborations Pharmaceuticals, Inc. (CPI) announced major updates to their drug discovery research and development pipeline aided by machine learning software.

Raleigh – The National Institute on Drug Abuse has awarded a $256,220 SBIR grant to Collaborations Pharmaceuticals, Inc.

Raleigh – The North Carolina Department of Commerce has awarded a matching award totaling $75,000 to Collaborations Pharmaceuticals, Inc. to support cutting edge science.

Raleigh – Collaborations Pharmaceuticals, Inc. (CPI) announced today that they have entered into an agreement with Stepan Company to license CPI’s MegaTox® machine learning software for predicting toxicology properties to aid their decision making and regulatory processes.

Raleigh – The National Institute of Environmental Health Sciences (NIEHS) has awarded $256,385 to Collaborations Pharmaceuticals, Inc. (CPI) to develop new machine learning models for prediction of acetylcholinesterase inhibition.

Raleigh – The National Institute of General Medical Sciences (NIGMS) has awarded $1,709,804 to Collaborations Pharmaceuticals, Inc. (CPI) to develop new capabilities in their Assay Central® machine learning software that will be applied to drug discovery research.

An international team of researchers has found that three commonly used antiviral and antimalarial drugs are effective in vitro at preventing replication of SARS-CoV-2, the virus that causes COVID-19.